Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2025-08-06 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025
Share Issue/Capital Change Classification · 1% confidence The document is a standard FF301 monthly return filed with the Hong Kong Exchange under Chapter 19B of the Listing Rules, detailing movements in authorized/issued share capital, share options, and other arrangements to issue shares. It is not an AGM presentation, earnings release, or annual/interim report, nor merely an announcement of a publication. It specifically concerns share capital movements and therefore best fits the “Share Issue/Capital Change” category.
2025-08-06 English
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Exchange announcement informing shareholders of a change in the company’s principal place of business. It does not present financials, votes, management changes, dividends, or other specific report content. It is a general regulatory announcement that does not fit into any narrowly defined category, making it a fallback “Regulatory Filings” (RNS).
2025-07-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025
Regulatory Filings Classification · 1% confidence The document is an HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” filed under Chapter 19B of the Exchange Listing Rules, detailing month-end movements in share capital, issued shares, share options, and other arrangements. It is a routine regulatory submission to the Exchange, not an earnings release, management discussion, or capital raising announcement. It does not constitute an annual or interim report itself but is a regular listing rule return, so it falls into the general Regulatory Filings category.
2025-07-07 English
Terms of Reference for the Nomination and Corporate Governance Committee
Governance Information Classification · 1% confidence The document is titled “Terms of Reference for the Nomination and Corporate Governance Committee” and lays out definitions, committee constitution, membership, authority, duties, reporting procedures, and publication provisions. It is not an announcement of results or capital changes, nor an earnings or annual report. Instead, it provides the internal governance rules and board committee structure, matching the “Governance Information” category.
2025-06-30 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document is a standalone announcement listing the company’s Board members and their committee roles as of a specified date. It does not present full financials, ESG metrics, or legal content, nor is it a short notice about a report publication or a proxy statement. It clearly falls under Board/Management Information, which covers disclosures of the composition and roles of the board and senior management.
2025-06-30 English
(1) APPOINTMENT OF NON-EXECUTIVE DIRECTOR&#x3b; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 1% confidence The document is a corporate announcement detailing the appointment of a new non-executive director and changes in the composition of board committees. It does not present financial results, a full report, or investor presentation materials, but rather changes in the company’s board and management structure. This matches the Board/Management Information category.
2025-06-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.